Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 294Lymphoma 204Lymphoma, Large B-Cell, Diffuse 168Sarcoma 142Precursor Cell Lymphoblastic Leukemia-Lymphoma 110Hodgkin Disease 85Lymphoma, Non-Hodgkin 79Burkitt Lymphoma 67Lymphoma, Follicular 62Leukemia 58Ovarian Neoplasms 51Triple Negative Breast Neoplasms 50Neoplasms 50Lymphoma, Mantle-Cell 48Multiple Myeloma 47Carcinoma, Hepatocellular 47Neuroblastoma 44Neoplasm Metastasis 42Lymphoma, B-Cell 33Lymphoma, Large-Cell, Anaplastic 31Recurrence 27Lymphoma, T-Cell, Peripheral 27Osteosarcoma 26Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 25Liposarcoma 25Leiomyosarcoma 25Urinary Bladder Neoplasms 23Lymphoma, Large-Cell, Immunoblastic 23Liver Neoplasms 22Endometrial Neoplasms 21

Interventions

temsirolimus 1dehydroftorafur 1Vincristine 1Sirolimus 1Razoxane 1Platinum 1Liver Transplantation 1Irinotecan 1Fluorouracil 1Doxorubicin 1Dexrazoxane 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
PRETEXT I Hepatoblastoma × Doxorubicin × Clear all
NCT00980460 2026-05-04

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
236 enrolled 18 charts
Gastrointestinal

PRETEXT I Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡